Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥50 years.
Chengchen ZhangAlejandro Amill-RosarioAbree JohnsonHaeyoung LeeO'Mareen SpenceDriss OraichiHarry SeifertValentine FranckSusan GambleHuifeng YunSusan dosReisPublished in: Seminars in arthritis and rheumatism (2024)
The findings suggest that RZV is not significantly associated with an increased risk of incident gout in the Medicare population aged ≥65 years.